Effects of secretory leukocyte protease inhibitor on the production of some cytokines and nitric oxide by murine peritoneal macrophages in response to lipopolysaccharide stimulation and M. Avium complex infection

Kekkaku

Volumn 74, Issue 7, 1999, Pages 563-570

  Sano, Chiaki ^b   Shimizu, Toshiaki ^b   Sato, Katsumasa ^b   Ogasawara, Keiko ^b   Tomioka, Haruaki ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b NONE

Author keywords

M. avium complex; Macrophage; SLPI; TGF

Indexed keywords

CANCER GROWTH FACTOR; CYTOKINE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; NITRIC OXIDE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; IMMUNOREGULATION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; PERITONEUM MACROPHAGE;

ANIMALS; CELLS, CULTURED; CYTOKINES; FEMALE; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; MYCOBACTERIUM AVIUM COMPLEX; NITRIC OXIDE; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SERINE PROTEINASE INHIBITORS;

EID: 0032812948     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. 1) [Annual Review 1994], 1994, 77-83.
2. Gavaillon M, Fitting C, Haeffner-Cavaillon N, et al.: Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect Immun. 1990 ; 58 : 2375-2382.
3. Jessop JJ, Henry SL, Hoffman T: Effects of serine protease inhibitor, TAME, on IL-1β in LPS-stimulated human monocytes: relationship between synthesis and release of a 33-kDa precursor and the 17-kDa biologically active species. Inflammation. 1993 ; 17 : 613-631.
4. Megyeri P, Pabst KM, Pabst MJ: Serine protease inhibitors block priming of monocytes for enhanced release of superoxide. Immunology. 1995 ; 86 : 629-635.
5. 1 - antitrypsin to inhibit degradation of fibrinogen by adherent polymorphonuclear leukocytes from normal subjects and patients with chronic granulomatous disease. Am Rev Respir Cell Mol Biol. 1992 ; 6 : 521-526.
6. Secretory leukoprotease inhibitor 1994 ; 13 : 363-370.
7. Asano S, Kida K, Koyama T, et al.: A morphologic study of lung secretory leukoprotease inhibitor in pneumonia. Am Rev Crit Care Med. 1995 ; 151 : 1576-1581.
8. Jin F, Nathan C, Radzioch D, et al.: Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell. 1997 ; 88 : 417-426.
9. 9) Prog Med. 1992 ; 12 : 1208-1219.
10. 10) The Lung. 1993 ; 1 : 13-17.
11. Masuda K, Kamimura T, Watanabe K, et al.: Pharmacological activity of the C-terminal and N-terminal domains of secretory leukoprotease inhibitor in vitro. Br J Pharmacol. 1995 ; 115 : 883-888.
12. Shimizu T, Tomioka H, Sato K, et al.: Effects of the Chinese traditional medicine Mao-Bushi-Saishin-To on therapeutic efficacy of a new benzoxazinorifamycin, against Mycobacterium avium infection in mice. Antimicrob Agents Chemother. 1999 ; 43 : 514-519.
13. Jin F, Nathan CF, Radzioch D, et al.: Lipopolysaccharide - related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect Immun. 1998 ; 66 : 2447-2452.
14. 2, and matrix metalloproteinases. J Cin Invest. 1997 ; 99 : 894-900.